Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma

Vol. 43 (3): 440-454, May – June, 2017

doi: 10.1590/S1677-5538.IBJU.2015.0521


ORIGINAL ARTICLE

Tastekin Ebru 1, Oz Puyan Fulya 1, Akdere Hakan 2, Yurut-Caloglu Vuslat 3, Sut Necdet 4, Can Nuray 1, Ozyilmaz Filiz 1
1 Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Turkey; 2 Department of Urology, Faculty of Medicine, Trakya University, Edirne, Turkey; 3 Department of Radiation Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey; 4 Department of Biostatistics, Faculty of Medicine, Trakya University, Edirne, Turkey

 

ABSTRACT

Purpose: Clear cell renal cell cancers frequently harbor Von Hippel-Lindau gene mutations, leading to stabilization of the hypoxia-inducible factors (HIFs) and their target genes. In this study, we investigated the relationship between vascular endotelial growth factor (VEGF), HIF-1α, HIF-2α, p53 positivity, microvessel density, and Ki-67 rates with prognostic histopathologic factors (Fuhrman nuclear grade, stage, and sarcomatoid differentiation) and survival in clear cell renal cell carcinomas.

Material and Methods: Seventy-two nephrectomy specimens diagnosed as clear cell renal cell carcinoma between 2000 and 2012 were reevaluated. Immunohistochemically VEGF, HIF-1α, HIF-2α, p53, CD34 (for microvessel density evaluation), and Ki-67 antibodies were applied to the tumor areas. The relationships of these antibodies with prognostic factors and survival rates were evaluated with statistical analyses.

Results: Mean survival time was 105.6 months in patients with ccRCC. Patients with high expression of VEGF, HIF-1α and HIF-2α positivity, a high Ki-67 proliferation index, and a high microvessel density evaluation score had a shorter survival time (p<0.05).

Conclusions: Our findings supported that with the use of these immunohistochemical markers, prognosis of renal cell carcinoma may be predicted at the first step of patient management. New treatment modalities targeted to HIF-1α and HIF-2α might be planned as well as VEGF-targeted therapies in the management of clear cell renal cell carcinomas.

Keywords: Carcinoma; Carcinoma, Renal Cell; Survival Rate

[Full Text]


print